The keynote speakers at the 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium will offer attendees valuable perspectives that reach beyond the boundaries of radiation oncology. Drawing on their broad expertise and visionary outlook, these speakers will illuminate the evolving landscape of radiopharmaceutical therapy and inspire participants to consider the wider context of their work. This year’s keynote presentations will reinforce the symposium’s theme, From Start-Up to State-of-the-Art: A Collaborative Journey, emphasizing innovation, collaboration and the dynamic progress shaping the field.
Stephen M. Hahn, MD, FASTRO, is the Chief Executive Officer and Board Chair of Nucleus RadioPharma and brings more than two decades of distinguished leadership in biotechnology, government, health care strategy, oncology medical practice, and translational/clinical research to this role. He served as the 24th Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) from 2019 to 2021 overseeing both COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics and clinical trials. Most recently, from 2021 to 2025, he was the Chief Executive Officer of Harbinger Health, a cancer diagnostics biotechnology company.
Prior to his FDA appointment, Dr. Hahn served as chief medical executive at the world-renowned MD Anderson Cancer Center in Houston. Prior to his role as chief medical executive, he served as deputy president and chief operating officer, where he was responsible for the day-to-day operations of the nation’s top cancer center, which included leading more than 21,000 employees and overseeing a $5.2 billion operating budget. Dr. Hahn was elevated to the role of Chief Operating Officer after serving as division head, department chair, and professor of Radiation Oncology. Prior to his executive leadership roles at MD Anderson, Dr. Hahn was the Chair of Radiation Oncology at the University of Pennsylvania’s Perelman School of Medicine.
Dr. Hahn focused his translational research efforts on the evaluation of the tumor microenvironment, signal transduction pathways involved in tumor response to therapies and proton therapy. He has authored more than 220 peer-reviewed original research articles and has experience in medical product development.
Dr. Hahn earned his MD from Temple University and received his BA in Biology from Rice University. He was an internal medicine resident at the University of California San Francisco before completing a fellowship and residency at the National Cancer Institute in Bethesda, Maryland.
Johannes Czernin, MD, is a Professor and Vice Chair of the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. He received his MD degree from the University of Vienna in 1983 and was board certified in Internal Medicine in Austria in 1989 and in Nuclear Medicine in 1996 in the US.
He was named Director of Nuclear Medicine at the David Geffen School of Medicine at UCLA in 1996 and currently serves as the Chief of the Ahmanson Translational Theranostics Division at UCLA.
The Division includes the Nuclear Medicine Clinic, a clinical imaging research program, a drug and probe development program with a strong underpinning in tumor biology, a preclinical imaging and biomedical radiochemistry center. His group successfully applied to the FDA for an NDA for a PSMA targeted PET imaging probe in prostate cancer. The Division collaborates within the department of molecular and medical pharmacology and across several other departments including urology, radiation oncology, oncology, surgery, radiology, neurology, pathology and others to advance preclinical and clinical theranostics.
Dr. Czernin is currently Editor-in-Chief of the Journal of Nuclear Medicine and is a past president of the Academy of Molecular Imaging. He has published more than 300 peer-reviewed research papers.
